THE LANCET
Infectious Diseases

Supplementary appendix 3

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Regan AK, Arriola CS, Couto P, Duca L, Loayza S, Nogareda F, de Almeida WAF, Antman J, Araya S, Avendaño Vigueras MA, Battaglia S, Brstilo I, Bustos P, Fandiño ME, Fasce R, Giovacchini CM, González Caro CI, von Horoch M, Juarez MV, Katz N, Olivares MF, da Silva DA, da Silva ET, Sotomayor V, Vergara N, Azziz-Baumgartner E, Ropero AM. Severity of influenza illness associated by seasonal influenza vaccination among hospitalized patients in four South American countries, 2013-2019: a surveillance-based cohort study

Table of Contents

Table S1. Summary of REVELAC-i countries and sites contributing influenza vaccine surveillance data between 2013 and 2019.

Country	Number of Sites	Years of Data Available	Number of Influenza Positive Cases	Outcome Information Complete			Included in Study
				LoS	ICU admission	Death	
Argentina	4	2013-2017	281	Y	Y	Y	Y
Brazil	29	2013-2016	1,343	Y	Y	Y	Y
Chile	6	2013-2019	2,354	Y	Y	Y	Y
Colombia	7	2013-2016	245	N	Y	Y	N
Costa Rica	7	2013	85	N	N	N	N
Ecuador	4	2014-15	62	Y	Y	N	N
Honduras	3	2013-14	37	N	N	N	N
Panama	10	2013	23	N	N	N	N
Paraguay	2	2013-2019	548	Y	Y	Y	Y
El Salvador	4	2013-14	14	N	N	N	N
Uruguay	7	2016, 2018	107	Y	Y	N	N
Total	**83**	**2013-2019**	**5,099**	**6**	**7**	**5**	**4**

Abbreviations: ICU, intensive care unit; LoS, length of stay

Table S2. Southern hemisphere vaccine formulation, 2013 to 2019 influenza seasons.

Virus subtype/ lineage	Influenza Season						
	2013	**2014**	**2015**	**2016**	**2017**	**2018**	**2019**
A/H1N1	A/California/7/2009 (H1N1)pdm09-like virus	A/California/7/2009 (H1N1)pdm-like virus	A/California/7/2009 (H1N1)pdm09-like virus	A/California/7/2009 (H1N1)pdm09-like virus	A/Michigan/45/2015 (H1N1)pdm09-like virus	A/Michigan/45/2015 (H1N1)pdm09-like virus	A/Michigan/45/2015 (H1N1)pdm09-like virus
A/H3N2	A/Victoria/361/2011 (H3N2)-like virus	A/Texas/50/2012 (H3N2)-like virus*	A/Switzerland/9715293/ 2013 (H3N2)-like virus	A/Hong Kong/4801/2014 (H3N2)-like virus	A/Hong Kong/4801/2014 (H3N2)-like virus*	A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus	A/Switzerland/8060/2017 (H3N2)-like virus
B/Yamagata	B/Wisconsin/1/2010-like virus†	B/Massachusetts/2/ 2012-like virus†	B/Phuket/3073/2013-like virus†	B/Phuket/3073/2013-like virus	B/Phuket/3073/2013-like virus	B/Phuket/3073/2013-like virus†	B/Phuket/3073/2013-like virus
B/Victoria	B/Brisbane/60/2008-like virus	B/Brisbane/60/2008-like virus	B/Brisbane/60/2008-like virus	B/Brisbane/60/2008-like virus†	B/Brisbane/60/2008-like virus†	B/Brisbane/60/2008-like virus	B/Colorado/06/2017-like virus†

*Indicates influenza season in which circulating influenza A/H3N2 virus did not genetically match the vaccine influenza A/H3N2 virus.
†B lineage included in trivalent influenza vaccines

Figure S1. Standardized mean differences* comparing characteristics of vaccinated and unvaccinated participants prior to and after application of inverse probability of treatment (vaccination) weights; where (a) represents results for young children 6-24 months of age, (b) represents results for adults 18-64 years of age with pre-existing medical conditions; and (c) represents results for older adults ≥65 years of age – Argentina, Brazil, Chile, and Paraguay, 2013-2019.

*represents range of values across multiple imputations

Table S3. Characteristics of cases hospitalized with laboratory-confirmed influenza, by severity of hospital admission – REVELAC-i network, Argentina, Brazil, Chile, and Paraguay, 2013-2019.

Characteristic	Children 6-24 months			Adults 18-64 years with pre-existing health conditions*			Older adults ≥65 years		
	% Admitted to ICU (n=87)	% In-hospital Death (n=12)	% No Severe Outcome* (n=386)	% Admitted to ICU (n=139)	% In-hospital Death (n=55)	% No Severe Outcome* (n=361)	% Admitted to ICU (n=271)	% In-hospital Death (n=220)	% No Severe Outcome* (n=1,180)
Country									
Argentina	2 (3·4)	0 (0)	57 (96·6)	..	..	..	15 (14·6)	0 (0)	88 (85·4)
Brazil	23 (17·2)	5 (3·7)	111 (82·8)	11 (34·4)	3 (9·4)	21 (65·6)	52 (26·8)	32 (16·5)	132 (68·0)
Chile	41 (15·5)	1 (0·4)	223 (84·5)	124 (26·8)	46 (10·0)	321 (69·5)	163 (15·5)	119 (11·3)	811 (77·2)
Paraguay	21 (10·9)	6 (3·1)	171 (89·1)	4 (15·4)	6 (23·1)	19 (73·1)	41 (17·8)	69 (30·0)	149 (64·8)
Year									
2013	22 (13·0)	6 (3·6)	147 (87·0)	8 (25·0)	5 (15·6)	23 (71·9)	60 (22·4)	55 (20·5)	183 (68·3)
2014	5 (5·9)	0 (0)	80 (94·1)	16 (26·7)	6 (10·0)	40 (66·7)	40 (18·6)	19 (8·8)	165 (76·7)
2015	12 (12·1)	0 (0)	87 (87·9)	19 (19·8)	7 (7·3)	74 (77·1)	51 (18·0)	38 (13·4)	206 (72·5)
2016	14 (16·1)	1 (1·1)	73 (83·9)	15 (26·8)	6 (10·7)	38 (67·9)	28 (17·8)	19 (12·1)	118 (75·2)
2017	6 (14·3)	1 (2·4)	36 (85·7)	25 (32·9)	10 (13·2)	48 (63·2)	38 (13·5)	34 (12·1)	220 (78·0)
2018	11 (16·9)	2 (3·1)	54 (83·1)	18 (24·7)	6 (8·2)	53 (72·6)	25 (11·8)	26 (12·3)	171 (81·0)
2019	17 (16·7)	2 (2·0)	85 (83·3)	38 (29·9)	15 (11·8)	85 (66·9)	29 (18·0)	29 (18·0)	117 (72·7)
Sex									
Male	52 (14·3)	9 (2·5)	311 (85·7)	89 (33·3)	41 (15·4)	166 (62·2)	127 (19·0)	99 (14·8)	488 (73·2)
Female	35 (12·2)	3 (1·0)	251 (87·8)	50 (19·8)	14 (5·5)	195 (77·1)	144 (15·8)	121 (13·3)	692 (76·0)
Smoking status									
Yes	..	..	..	40 (28·2)	17 (12·0)	97 (68·3)	58 (16·2)	37 (14·1)	185 (70·3)
No	..	..	..	99 (26·2)	38 (10·1)	264 (69·8)	213 (22·1)	183 (13·9)	995 (75·7)
Pre-existing medical condition									
No pre-existing condition	55 (12·4)	4 (0·9)	387 (87·6)	..	..	..	64 (13·0)	67 (13·6)	386 (78·6)
1 condition	31 (15·7)	8 (4·0)	167 (84·3)	27 (26·7)	14 (13·9)	69 (68·3)	83 (16·7)	63 (12·7)	375 (75·6)
2 conditions	0 (0)	0 (0)	9 (100)	22 (43·1)	4 (7·8)	29 (56·9)	68 (22·3)	48 (15·7)	209 (68·5)
≥3 conditions	1 (33·3)	0 (0)	2 (66·7)	90 (24·5)	37 (10·1)	263 (71·5)	56 (19·6)	42 (14·7)	210 (73·4)
At least 1 pre-existing condition†	32 (15·5)	8 (3·9)	175 (84·5)	139 (100)	55 (100)	361 (100)	232 (18·3)	175 (13·8)	934 (73·8)
Prior influenza vaccination									
Yes	..	..	..	30 (23·4)	11 (8·6)	94 (73·4)	113 (17·4)	68 (10·2)	524 (78·4)
No	..	..	..	109 (27·8)	44 (11·2)	267 (68·1)	158 (16·9)	152 (16·7)	656 (72·1)
Antiviral medication use									
Any antiviral medication use	35 (16·0)	4 (1·8)	184 (84·0)	93 (31·6)	37 (12·6)	190 (64·6)	149 (17·7)	98 (11·6)	638 (75·6)
≤2 days after symptom onset	11 (17·5)	0 (0)	52 (82·5)	38 (34·2)	12 (10·8)	69 (62·2)	42 (16·2)	24 (9·3)	203 (78·4)
>3 days after symptom onset	5 (6·8)	0 (0)	68 (93·2)	49 (30·8)	22 (13·8)	103 (64·8)	68 (18·2)	47 (12·6)	271 (72·7)
No antiviral medication use	52 (12·1)	8 (1·9)	378 (87·9)	46 (20·4)	18 (8·0)	171 (75·7)	122 (16·6)	122 (16·6)	542 (73·8)
Time from symptom onset to admission									
0 days	19 (15·2)	2 (1·6)	106 (84·8)	38 (27·5)	17 (12·3)	92 (66·7)	60 (16·9)	46 (13·0)	1023 (74·6)
1-2 days	24 (11·1)	5 (2·3)	193 (88·9)	43 (24·7)	16 (9·2)	125 (71·8)	79 (14·3)	62 (11·2)	438 (79·2)
3-4 days	24 (14·6)	4 (2·4)	140 (85·4)	25 (21·0)	12 (10·1)	90 (75·6)	71 (19·2)	70 (19·0)	254 (68·8)
5-10 days	20 (14·0)	1 (0·7)	123 (86·0)	33 (37·1)	10 (11·2)	54 (60·7)	61 (20·2)	42 (13·9)	222 (73·5)
Virus type/subtype of infection									
Influenza A/H3N2	29 (12·7)	3 (1·3)	199 (87·3)	60 (26·5)	23 (10·2)	157 (69·5)	128 (14·7)	101 (11·6)	679 (78·0)

6

Influenza A/H1N1	40 (14·8)	9 (3·3)	230 (85·2)	69 (29·0)	29 (12·2)	160 (67·2)	104 (21·8)	85 (17·8)	333 (69·7)
Influenza A/Unknown subtype	3 (11·5)	0 (0)	23 (88·5)	0 (0)	0 (0)	0 (0)	9 (37·5)	5 (20·8)	11 (45·8)
Influenza B/Yamagata	4 (15·4)	0 (0)	22 (84·6)	6 (15·8)	1 (2·6)	31 (81·6)	12 (14·0)	8 (9·3)	69 (80·2)
Influenza B/Victoria	6 (27·3)	0 (0)	16 (72·7)	1 (20·0)	0 (0)	4 (80·0)	4 (13·3)	1 (3·3)	25 (83·3)
Influenza B/Unknown lineage	5 (6·5)	0 (0)	72 (93·5)	3 (33·3)	2 (22·2)	5 (55·6)	11 (21·2)	15 (28·8)	31 (59·6)
Viral co-infection detected									
Yes	16 (23·2)	3 (4·3)	53 (76·8)	1 (33·3)	0 (0)	2 (66·7)	5 (17·9)	3 (10·7)	21 (75·0)
Respiratory Syncytial Virus	4 (14·3)	0 (0)	24 (85·7)	1 (33·3)	0 (0)	2 (66·7)	3 (23·1)	2 (0·1)	10 (76·9)
Parainfluenza	1 (33·3)	0 (0)	2 (66·7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)
Human metapneumovirus	1 (33·3)	0 (0)	2 (66·7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (100)
Adenovirus	0 (0)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	1 (20·0)	0 (0)	4 (80·0)
Other viruses	10 (29·4)	3 (8·8)	24 (70·6)	0 (0)	0 (0)	0 (0)	1 (100)	1 (100)	0 (0)
No	71 (12·2)	9 (1·6)	509 (87·8)	138 (26·7)	55 (10·6)	359 (69·4)	266 (17·2)	217 (14·0)	1159 (74·8)

NOTE: characteristics presented in Table 1 summarize those from a single randomly selected imputed dataset.

ICU, intensive care unit

·· Data not applicable or available

[*] No severe outcome indicated the patient was not admitted to intensive care unit and did not die in hospital.

[†] Diagnosis of at least one pre-existing medical condition including diabetes, asthma, metabolic, immune system, nervous system, renal and liver disorders.

Figure S2. Distribution of length of stay among influenza hospitalized individuals, by vaccination status; where (a) represents results for children 6-24 months of age, (b) represents results for adults 18-64 years of age with pre-existing medical conditions; and (c) represents results for older adults ≥65 years of age – Argentina, Brazil, Chile, and Paraguay, 2013-2019.

Table S4. Cumulative probability of discharge derived from survival analysis of length of hospital stay among children 6-24 months of age, by influenza vaccination status – Argentina, Brazil, Chile, and Paraguay, 2013-2019.

Time (in days)	Unvaccinated		Partially Vaccinated		Fully Vaccinated	
	Cumulative Survival Probability (95% CI)	Cumulative Probability of Discharge (95% CI)	Cumulative Survival Probability (95% CI)	Cumulative Probability of Discharge (95% CI)	Cumulative Survival Probability (95% CI)	Cumulative Probability of Discharge (95% CI)
0	0.98 (0.96, 0.99)	0.02 (0.01, 0.04)	0.99 (0.97, 100)	0.01 (0.0, 0.03)	100	0
1	0.89 (0.86, 0.93)	0.11 (0.07, 0.14)	0.93 (0.89, 0.96)	0.07 (0.04, 0.11)	0.96 (0.91, 100)	0.04 (0.0, 0.09)
2	0.80 (0.76, 0.84)	0.20 (0.16, 0.24)	0.82 (0.77, 0.88)	0.18 (0.12, 0.23)	0.86 (0.78, 0.94)	0.14 (0.06, 0.22)
3	0.66 (0.61, 0.71)	0.34 (0.29, 0.39)	0.71 (0.65, 0.78)	0.29 (0.22, 0.35)	0.67 (0.57, 0.79)	0.33 (0.21, 0.43)
4	0.54 (0.50, 0.60)	0.46 (0.40, 0.50)	0.56 (0.50, 0.64)	0.44 (0.36, 0.50)	0.54 0.44, 0.67)	0.56 (0.33, 0.56)
5	0.41 (0.36, 0.46)	0.59 (0.54, 0.64)	0.45 (0.39, 0.53)	0.55 (0.47, 0.61)	0.43 (0.33, 0.56)	0.57 (0.44, 0.67)
6	0.34 (0.29, 0.39)	0.66 (0.61, 0.71)	0.41 (0.35, 0.49)	0.59 (0.51, 0.65)	0.36 (0.26, 0.49)	0.64 (0.51, 0.74)
7	0.28 (0.23, 0.33)	0.72 (0.67, 0.77)	0.32 (0.26, 0.39)	0.68 (0.61, 0.74)	0.27 (0.18, 0.40)	0.73 (0.60, 0.82)
8	0.24 (0.20, 0.29)	0.76 (0.71, 0.80)	0.27 (0.21, 0.34)	0.73 (0.66, 0.89)	0.20 (0.12, 0.32)	0.80 (0.68, 0.88)
9	0.21 (0.17, 0.25)	0.79 (0.75, 0.83)	0.22 (0.17, 0.29)	0.78 (0.71, 0.83)	0.17 (0.10, 0.29)	0.83 (0.71, 0.90)
10	0.17 (0.14 0.21)	0.83 (0.79, 0.86)	0.18 (0.13, 0.24)	0.82 (0.76, 0.87)	0.14 (0.08, 0.25)	0.86 (0.75, 0.92)
11	0.15 (0.11, 0.19)	0.85 (0.81, 0.89)	0.17 (0.12, 0.23)	0.83 (0.77, 0.88)	0.13 (0.08, 0.25)	0.87 (0.75, 0.82)
12	0.14 (0.11, 0.18)	0.86 (0.82, 0.89)	0.12 (0.08, 0.17)	0.88 (0.83, 0.92)	0.08 (0.04, 0.18)	0.92 (0.82, 0.96)
13	0.12 (0.09, 0.16)	0.88 (0.84, 0.91)	0.08 (0.05, 0.13)	0.92 (0.87, 0.95)	0.07 (0.03, 0.16)	0.93 (0.84, 0.97)
14	0.12 (0.09, 0.15)	0.88 (0.85, 0.91)	0.06 (0.03, 0.09)	0.94 (0.91, 0.97)	0.06 (0.02, 0.15)	0.94 (0.85, 0.98)
15	0.11 (0.08, 0.14)	0.89 (0.86, 0.92)	0.05 (0.03, 0.09)	0.95 (0.91, 0.97)	0.04 (0.01, 0.13)	0.96 (0.87, 0.99)
16	0.09 (0.07, 0.13)	0.91 (0.87, 0.93)	0.04 (0.02, 0.08)	0.96 (0.92, 0.98)	0.04 (0.01, 0.13)	0.96 (0.87, 0.99)
17	0.08 (0.06, 0.11)	0.92 (0.89, 0.94)	0.04 (0.02, 0.07)	0.96 (0.93, 0.98)	0.04 (0.01, 0.13)	0.96 (0.87, 0.99)
18	0.07 (0.05, 0.10)	0.93 (0.90, 0.95)	0.03 (0.01, 0.07)	0.97 (0.93, 0.99)	0.04 (0.01, 0.13)	0.96 (0.87, 0.99)
19	0.07 (0.05, 0.10)	0.93 (0.90, 0.95)	0.03 (0.01, 0.07)	0.97 (0.93, 0.99)	0.04 (0.01, 0.13)	0.96 (0.87, 0.99)
20	0.07 (0.05, 0.10)	0.93 (0.90, 0.95)	0.02 (0.01, 0.06)	0.98 (0.94, 0.99)	0.03 (0.07, 0.11)	0.97 (0.89, 0.93)
21	0.06 (0.04, 0.09)	0.94 (0.91, 0.96)	0.02 (0.01, 0.06)	0.98 (0.94, 0.99)	0.03 (0.07, 0.11)	0.97 (0.89, 0.93)
22	0.06 (0.04, 0.09)	0.94 (0.91, 0.96)	0.02 (0.01, 0.05)	0.98 (0.95, 0.99)	0.03 (0.07, 0.11)	0.97 (0.89, 0.93)
23	0.06 (0.04, 0.09)	0.94 (0.91, 0.96)	0.02 (0.01, 0.05)	0.98 (0.95, 0.99)	0.03 (0.07, 0.11)	0.97 (0.89, 0.93)
24	0.05 (0.03, 0.08)	0.95 (0.92, 0.97)	0.02 (0.01, 0.05)	0.98 (0.95, 0.99)	0.03 (0.07, 0.11)	0.97 (0.89, 0.93)
26	0.05 (0.03, 0.08)	0.95 (0.92, 0.97)	0.01 (0.01, 0.05)	0.99 (0.95, 0.99)	0.03 (0.07, 0.11)	0.97 (0.89, 0.93)
27	0.05 (0.03, 0.08)	0.95 (0.92, 0.97)	0.01 (0.01, 0.05)	0.99 (0.95, 0.99)	0.03 (0.07, 0.11)	0.97 (0.89, 0.93)
28	0.05 (0.03, 0.07)	0.95 (0.93, 0.97)	0.01 (0.01, 0.05)	0.99 (0.95, 0.99)	0.03 (0.07, 0.11)	0.97 (0.89, 0.93)
29	0.05 (0.03, 0.07)	0.95 (0.93, 0.97)	0.01 (0.0, 0.04)	0.99 (0.96, 100)	0.03 (0.07, 0.11)	0.97 (0.89, 0.93)
30	0.05 (0.03, 0.07)	0.95 (0.93, 0.97)	0.01 (0.0, 0.04)	0.99 (0.96, 100)	0.01 (0.0, 0.10)	0.99 (0.90, 100)

Table S5. Risk of intensive care unit admission or in-hospital death among influenza hospitalized individuals associated with influenza vaccination status, by number of pre-existing health conditions – Argentina, Brazil, Chile, and Paraguay, 2013-2019.

Influenza virus type/subtype	Children 6-24 months			Adult 18-64 years of age with pre-existing medical conditions		Older adults ≥65 years	
	Unvaccinated	Partially vaccinated	Fully vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Vaccinated
No pre-existing conditions							
n (%)	39 (14·1)	15 (12·2)	3 (6·5)	--	--	47 (20·8)	20 (21·3)
OR (95% CI)	Reference	0·81 (0·42, 1·55)	0·43 (0·13, 1·47)	--	--	Reference	0·98 (0·56, 1·72)
aOR (95% CI)*	Reference	0·50 (0·31, 0·82)†	0·43 (0·18, 1·00)	--	--	Reference	1·16 (0·74, 1·84)
One pre-existing condition							
n (%)	18 (16·8)	8 (14·0)	2 (8·7)	30 (29·1)	3 (8·8)	79 (24·3)	41 (18·5)
OR (95% CI)	Reference	0·78 (0·32, 1·91)	--	Reference	0·40 (0·08, 2·01)	Reference	0·73 (0·47, 1·14)
aOR (95% CI)*	Reference	0·74 (0·38, 1·45)	--	Reference	0·35 (0·57, 2·15)	Reference	0·77 (0·53, 1·12)
Two pre-existing conditions							
n (%)	--	--	--	30 (33·3)	6 (42·8)	78 (31·7)	38 (22·7)
OR (95% CI)	--	--	--	Reference	1·24 (0·30, 5·15)	Reference	0·62 (0·35, 1·09)
aOR (95% CI)*	--	--	--	Reference	1·72 (0·36, 8·30)	Reference	0·57 (0·35, 0·93)†
Three or more pre-existing conditions							
n (%)	--	--	--	67 (32·1)	23 (32·9)	59 (34·3)	36 (28·6)
OR (95% CI)	--	--	--	Reference	0·92 (0·33, 2·56)	Reference	0·71 (0·40, 1·26)
aOR (95% CI)*	--	--	--	Reference	1·06 (0·40, 2·85)	Reference	0·81 (0·49, 1·34)

* Logistic regression models were weighted by inverse probability treatment weights and adjusted for antiviral medication use, duration of illness at admission, and calendar week (fit as a cubic spline); pooled odds ratios were calculated using the pool() function in R, which averages the estimates across the 20 imputed datasets and calculates total variance across the repeated analyses using Rubin's rule. † Significant at P<0.05.

Table S6. Cumulative probability of discharge derived from survival analysis of length of hospital stay among adults 18-64 years of age with pre-existing medical conditions and older adults ≥65 years of age, by influenza vaccination status – Argentina, Brazil, Chile, and Paraguay, 2013-2019.

Time (in days)	Adults with Medical Conditions				Older Adults			
	Unvaccinated		Vaccinated		Unvaccinated		Vaccinated	
	Cumulative Survival Probability (95% CI)	Cumulative Probability of Discharge (95% CI)	Cumulative Survival Probability (95% CI)	Cumulative Survival Probability (95% CI)	Cumulative Survival Probability (95% CI)	Cumulative Probability of Discharge (95% CI)	Cumulative Survival Probability (95% CI)	Cumulative Probability of Discharge (95% CI)
0	0.99 (0.99, 100)	0.01 (0.0, 0.01)	0.97 (0.95, 100)	0.03 (0.0, 0.05)	0.98 (0.97. 0.99)	0.02 (0.01, 0.03)	0.98 (0.97, 0.99)	0.02 (0.01, 0.03)
1	0.95 (0.93, 0.97)	0.05 (0.03, 0.07)	0.91 (0.87, 0.97)	0.09 (0.03, 0.13)	0.91 (0.89, 0.93)	0.09 (0.07, 0.11)	0.94 (0.92, 0.96)	0.06 (0.04, 0.08)
2	0.89 (0.85, 0.92)	0.11 (0.08, 0.15)	0.85 (0.79, 0.92)	0.15 (0.08, 0.21)	0.84 (0.82, 0.87)	0.16 (0.13, 0.18)	0.86 (0.83, 0.89)	0.14 (0.11, 0.17)
3	0.81 (0.77, 0.85)	0.19 (0.15, 0.23)	0.81 (0.74, 0.88)	0.19 (0.12, 0.26)	0.79 (0.77, 0.82)	0.21 (0.18, 0.23)	0.79 (0.76, 0.83)	0.21 (0.17, 0.24)
4	0.72 (0.68, 0.77)	0.28 (0.23, 0.32)	0.73 (0.65, 0.81)	0.27 (0.19, 0.35)	0.72 (0.69, 0.75)	0.28 (0.25, 0.31)	0.69 (0.66, 0.73)	0.31 (0.27, 0.34)
5	0.65 (0.60, 0.70)	0.35 (0.30, 0.40)	0.64 (0.56, 0.74)	0.36 (0.26, 0.44)	0.64 (0.61, 0.67)	0.36 (0.33, 0.39)	0.61 (0.58, 0.65)	0.39 (0.35, 0.42)
6	0.57 (0.52, 0.62)	0.43 (0.38, 0.48)	0.53 (0.45, 0.63)	0.47 (0.37, 0.55)	0.56 (0.53, 0.59)	0.44 (0.41, 0.47)	0.53 (0.50, 0.58)	0.47 (0.42, 0.50)
7	0.50 (0.45, 0.56)	0.50 (0.44, 0.55)	0.47 (0.38, 0.56)	0.53 (0.44, 0.62)	0.48 (0.45, 0.52)	0.52 (0.48, 0.55)	0.45 (0.41, 0.49)	0.55 (0.51, 0.59)
8	0.45 (0.41, 0.50)	0.55 (0.50, 0.59)	0.35 (0.18, 0.45)	0.65 (0.55, 0.82)	0.41 (0.37, 0.44)	0.59 (0.56, 0.63)	0.39 (0.35, 0.43)	0.61 (0.57, 0.65)
9	0.40 (0.36, 0.46)	0.60 (0.54, 0.64)	0.31 (0.24, 0.41)	0.69 (0.59, 0.76)	0.35 (0.32, 0.38)	0.65 (0.62, 0.68)	0.32 (0.28, 0.36)	0.68 (0.64, 0.72)
10	0.35 (0.31, 0.41)	0.65 (0.59, 0.69)	0.28 (0.21, 0.37)	0.72 (0.63, 0.79)	0.32 (0.29, 0.35)	0.68 (0.65, 0.71)	0.26 (0.23, 0.30)	0.74 (0.70, 0.77)
11	0.32 (0.28, 0.37)	0.68 (0.63, 0.72)	0.23 (0.16, 0.32)	0.77 (0.68, 0.84)	0.28 0.26, 0.31)	0.72 (0.69, 0.74)	0.22 (0.19, 0.25)	0.78 (0.75, 0.81)
12	0.29 (0.25, 0.34)	0.71 (0.66, 0.75)	0.20 (0.14, 0.29)	0.80 (0.71, 0.86)	0.25 (0.23, 0.28)	0.75 (0.72, 0.77)	0.19 (0.16, 0.23)	0.81 (0.77, 0.84)
13	0.28 (0.23, 0.32)	0.72 (0.68, 0.77)	0.19 (0.13, 0.27)	0.81 (0.73, 0.87)	0.23 (0.20, 0.25)	0.77 (0.75, 0.80)	0.16 (0.13, 0.19)	0,84 (0.81, 0.87)
14	0.25 (0.21, 0.30)	0.75 (0.70, 0.79)	0.16 (0.11, 0.24)	0.84 (0.76, 0.89)	0.19 (0.17, 0.22)	0.81 (0.78, 0.83)	0.15 (0.12, 0.18)	0.85 (0.82, 0.88)
15	0.22 (0.18, 0.26)	0.78 (0.74, 0.82)	0.16 (0.11, 0.24)	0.84 (0.76, 0.89)	0.18 (0.15, 0.20)	0.82 (0.80, 0.85)	0.14 (0.11, 0.17)	0.86 (0.83, 0.89)
16	0.20 (0.17, 0.25)	0.80 (0.75, 0.83)	0.15 (0.10, 0.23)	0.85 (0.77, 0.90)	0.15 (0.13, 0.18)	0.85 (0.82, 0.87)	0.12 (0.09, 0.15)	0.88 (0.85, 0.91)
17	0.18 (0.15, 0.23)	0.82 (0.77, 0.85)	0.15 (0.10, 0.23)	0.85 (0.77, 0.90)	0.14 (0.12, 0.16)	0.86 (0.84, 0.88)	0.11 (0.08, 0.13)	0.89 (0.87, 0.92)
18	0.16 (0.13, 0.20)	0.84 (0.80, 0.87)	0.15 (0.10, 0.23)	0.85 (0.77, 0.90)	0.12 (0.10, 0.14)	0.88 (0.86, 0.90)	0.09 (0.07, 0.12)	0.91 (0.88, 0.93)
19	0.15 (0.12, 0.19)	0.85 (0.81, 0.88)	0.15 (0.10, 0.23)	0.85 (0.77, 0.90)	0.11 (0.09, 0.13)	0.89 (0.87, 0.91)	0.09 (0.07, 0.11)	0.91 (0.93, 0.89)
20	0.13 (0.10, 0.17)	0.87 (0.83, 0.90)	0.15 (0.10, 0.23)	0.85 (0.77, 0.90)	0.10 (0.08, 0.12)	0.90 (0.88, 0.92)	0.07 (0.05, 0.10)	0.93 (0.90, 0.95)
21	0.11 (0.09, 0.15)	0.89 (0.85, 0.91)	0.14 (0.09, 0.22)	0.86 (0.78, 0.91)	0.09 (0.07, 0.11)	0.91 (0.89, 0.93)	0.07 (0.05, 0.10)	0.93 (0.90, 0.95)
22	0.11 (0.08, 0.14)	0.89 (0.86, 0.92)	0.13 (0.09, 0.22)	0.87 (0.78, 0.91)	0.08 (0.06, 0.10)	0.92 (0.90, 0.95)	0.06 (0.04, 0.08)	0.94 (0.92, 0.96)
23	0.10 (0.07, 0.13)	0.90 (0.87, 0.93)	0.11 (0.07, 0.18)	0.89 (0.82, 0.93)	0.07 (0.06, 0.09)	0.93 (0.91, 0.94)	0.05 (0.04, 0.07)	0.95 (0.93, 0.96)
24	0.09 (0.07, 0.13)	0.91 (0.87, 0.93)	0.10 (0.06, 0.16)	0.90 (0.84, 0.94)	0.07 (0.05, 0.09)	0.93 (0.95, 0.91)	0.05 (0.03, 0.07)	0.95 (0.93, 0.97)
25	0.09 (0.07, 0.12)	0.91 (0.88, 0.93)	0.10 (0.06, 0.16)	0.90 (0.84, 0.94)	0.06 (0.05, 0.08)	0.94 (0.92, 0.95)	0.05 (0.03, 0.07)	0.95 (0.93, 0.97)
26	0.08 (0.06, 0.11)	0.92 (0.89, 0.94)	0.07 (0.03, 0.13)	0.93 (0.87, 0.97)	0.06 (0.04, 0.07)	0.94 (0.93, 0.96)	0.04 (0.03, 0.05)	0.06 (0.95, 0.97)
27	0.07 (0.05, 0.11)	0.93 (0.89, 0.95)	0.05 (0.02, 0.11)	0.95 (0.89, 0.98)	0.06 (0.05, 0.07)	0.94 (0.93, 0.95)	0.04 (0.03, 0.05)	0.06 (0.95, 0.97)
28	0.07 (0.05, 0.10)	0.93 (0.90, 0.95)	0.05 (0.02, 0.11)	0.95 (0.89, 0.98)	0.06 (0.04, 0.07)	0.94 (0.93, 0.96)	0.04 (0.02, 0.05)	0.96 (0.95, 0.98)
29	0.06 (0.04, 0.09)	0.94 (0.91, 0.96)	0.05 (0.02, 0.11)	0.95 (0.89, 0.98)	0.06 (0.04, 0.07)	0.94 (0.93, 0.96)	0.04 (0.02, 0.05)	0.96 (0.95, 0.98)
30	0.06 (0.04, 0.09)	0.94 (0.91, 0.96)	0.04 (0.02, 0.10)	0.96 (0.90, 0.98)	0.05 (0.04, 0.07)	0.95 (0.03, 0.06)	0.03 (0.02, 0.05)	0.97 (0.95, 0.98)